By now, you've heard all about Botox—the treatment designed to freeze muscles and smooth facial wrinkles. But did you know that there are alternatives to Botox? One such alternative is Xeomin (pronounced Zeo-min).
To learn more about Xeomin, click one of the questions below:
Xeomin is an FDA-approved medication that is injected into the muscles in order to freeze them and temporarily smooth moderate to severe frown lines between the eyebrows, AKA glabellar lines. Xeomin contains a highly purified neurotoxin.
(Xeomin injections are also approved to treat adults with cervical dystonia and blepharospasms, AKA eyelid spasms, but we're going to focus on Xeomin's cosmetic uses here).
Frowning and squinting cause the facial muscles between your eyebrows to contract. Over time, those contractions cause frown lines to form. Xeomin temporarily reduces this muscle activity by paralyzing these facial muscles, which helps to smooth frown lines.
During your treatment, which takes about 10-20 minutes, your practitioner will inject Xeomin into your forehead. They may use a topical anesthetic or a cold pack to reduce discomfort.
Like Botox, Xeomin is a botulinum toxin type A injectable. Xeomin's formula is actually very similar to Botox, minus a few proteins, and patients often can't tell the difference. However, Xeomin is not as well known as Botox. It's also usually a bit cheaper.
You should see results a little less than a week after your treatment, sometimes as soon as 3–4 days later. Full results take about 30 days to materialize.
About three months, according to clinical trials by the manufacturer, whi warns that the results may last significantly longer or shorter in individual patients.
Most adults are eligible for Xeomin (the manufacturer doesn't recommend it for anyone younger than 18).
Headache is the most common side effect of Xeomin when used to treat glabellar lines. Other possible side effects include:
Xeomin may cause other serious side effects including allergic reactions. Read all of the safety considerations for Xeomin here.
The information contained in this article is from Xeomin's website.